Prostate Cancer

Quality Of Immune Response To Dendritic Cell Vaccine Tied To Route Of Administration

Published in Cancer Weekly, May 15th, 2001

by N.R. Saltmarsh, staff medical writer - Immune response of prostate cancer patients receiving a dendritic cell (DC) vaccine varies depending on how the vaccine is delivered, pathologists report.

Intradermal and intralymphatic routes of administration were more likely to induce interferon-gamma production, while intravenous injection was better at generating antigen (Ag)-specific antibodies (Abs), noted L. Fong and colleagues at Stanford University.

They used Ag-pulsed DC as a tumor vaccine in a pilot clinical trial involving 21 patients with metastatic prostate cancer. The patients received two monthly injections of DC derived from their...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-05-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry